Holen Sie sich die Stockscreener-App
13.34
8.19%
-1.19
Handel nachbörslich:
13.34
Generate Biomedicines Inc Aktie (GENB) Neueste Nachrichten
This AI biotech stock landed a $10.4 million Nvidia investment - MSN
symbol__ Stock Quote Price and Forecast - CNN
Can Nvidia’s Backing Reframe Generate Biomedicines (GENB) as a Scaled AI Drug Developer? - simplywall.st
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment - simplywall.st
This AI Biotech Stock Landed a $10.4 Million Nvidia Investment - Yahoo Finance
A Deep Dive Into Nvidia’s Latest Portfolio Moves - Investing.com
IPO Tracker 2026: Parabilis follows hefty Regeneron deal with IPO push - BioSpace
Generate Biomedicines (GENB) News Flow - Moomoo
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - The Chronicle-Journal
Trades UpdateBuying More Generate BiomedicinesDeepDive - Moomoo
AI Protein Design Market 2026-2033 | Market Growth to FY (Q2) - openPR.com
Flagship entities disclose large GENB holdings, Flagship Pioneering holds 48.9% (GENB) - Stock Titan
Generate Biomedicines (NASDAQ: GENB) exec Michael Nally holds 5.2% stake - Stock Titan
GENB : Generate Biomedicines, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
GENB: Generate Biomedicines, Inc.Brokerage Recommendations Chart - Zacks Investment Research
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Programmable Biology: Will GENB Generate Investor Interest? - RTTNews
Generate Biomedicines, Inc. Stock 12‑Month Price Target Raised to $25.4, Implies 57% Upside - TradingView
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
Generate Biomedicines, Inc. (GENB) Ps Ratio (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Enterprise Value - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Free Cash Flow (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Revenue (Quarterly) - Zacks Investment Research
Dividend HistoryGenerate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Book Value - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Price To Free Cash Flow - Zacks Investment Research
All News for GENB : Generate Biomedicines, Inc. - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Price To Cash Flow - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Eps Diluted (TTM) - Zacks Investment Research
Generate Biomedicines (GENB) Earnings Date and Reports 2026 - MarketBeat
Should I buy Generate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Net Income (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Total Expenses (Quarterly) - Zacks Investment Research
What is the current Price Target and Forecast for Generate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Cash From Operations (TTM) - Zacks Investment Research
Number of shareholders of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
GENB : Generate Biomedicines, Inc. Key Company Details - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Beta - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Dividend (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Total Long Term Debt (Quarterly) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Gross Margin (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Total Liabilities - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Cash From Financing (Quarterly) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Revenue (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Price Book Value - Zacks Investment Research
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):